The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Peptide ELISA: Use at an assay dependent dilution. Antibody detection limit dilution 1/64,000.
WB: Use at a concentration of 1 - 3 µg/ml. Detects a band of approximately 70 kDa (predicted molecular weight: 70 kDa).
An additional band of unknown identity was also consistently observed at 22kDa. This band was successfully blocked by incubation with the immunising peptide.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Defects in CHRNA4 are the cause of nocturnal frontal lobe epilepsy type 1 (ENFL1) [MIM:600513]; also symbolized ADNFLE. ENFL1 is an autosomal dominant epilepsy characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements.
Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha-4/CHRNA4 sub-subfamily.